Interferon in the Treatment of Hairy Cell Leukemia and Chronic Myelogenous Leukemia

  • Norbert Niederle
  • Otto Kloke
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Interferons have enjoyed increasing interest since their discovery in 1957 (1) and may be regarded as prototype biological substances in the systemic treatment of cancer. Besides natural interferon (IFN) alpha produced by leukocyte suspensions, highly purified material produced by recombinant DNA technology became available in 1981 (2–4). These different types of IFN have been shown to be effective against various malignancies. The most impressive results have been achieved in hematologic disorders (5–8). However, data are difficult to compare since in these phase I and II trials different products were used and, moreover, administered in different routes, doses and schedules. Here we will review clinical experience with IFNs in the treatment of hairy cell leukemia and chronic myelogenous leukemia.


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Alpha Interferon Interferon Therapy Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc Ser B 1957 (147):258–267CrossRefGoogle Scholar
  2. 2.
    Goeddel DV, Yelverton E, Ullrich A et al.:Human leukocyte interferon produced by E. coli is biologically active. Nature (Lond) 1980 (287):411–416CrossRefGoogle Scholar
  3. 3.
    Nagata S, Taira H, Hall A et al.: Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature (Lond) 1980 (284):316–320CrossRefGoogle Scholar
  4. 4.
    Pestka S: Interferon: A decade of accomplishments, foundations of the future in research and therapy. Semin Hematol 1986 (23):27–37PubMedGoogle Scholar
  5. 5.
    Oldham RK: Biologicals for cancer treatment: Interferons. Hosp Prac 1985:71–91Google Scholar
  6. 6.
    Niederle N, Schmidt CG: Klinische Erfahrungen mit Interferon in der Tumortherapie. In: Schuff-Werner P, Pfizenmaier K (eds) Entwicklung, Pruefung und Anwendung von biologisch aktiven Substanzen in der Krebstherapie. Aktuelle Onkologie 1985 (24):116–136, Muenchen, Bern, Wien: Zuckschwerdt-VerlagGoogle Scholar
  7. 7.
    Krown SE: Interferons and interferon inducers in cancer treatment. Semin Oncol 1986 (13):207–217PubMedGoogle Scholar
  8. 8.
    Goldstein D, Laszlo J: Interferon therapy in cancer: From imaginon to interferon. Cancer Res 1986 (46):4315- 4329PubMedGoogle Scholar
  9. 9.
    Ewald O: Die leukaemische Retikuloendotheliosis. Dtsch Arch Klin Med 1923 (142):222–228Google Scholar
  10. 10.
    Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 1958 (13):609–630PubMedGoogle Scholar
  11. 11.
    Catovsky D: Prolymphocyte and hairy cell leukemias. In: Gunz FW, Henderson ES (eds) Leukemia, 4 ed. 1983:759–781, New York-London: Grüne and StrattonGoogle Scholar
  12. 12.
    Flandrin G, Sigaux F, Sebahoun G et al.: Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol 1984 (11) (Suppl 2):458–471PubMedGoogle Scholar
  13. 13.
    Mende S, Fuelle H-H, Weissenfels I: Diagnose und Differentialdiagnose der Haarzell-Leukaemie (“Hairy cell leukaemia”; “Leukaemische Retikuloendotheliose”). Blut 1975 (30):163–174PubMedCrossRefGoogle Scholar
  14. 14.
    Catovsky D, Pettit JE, Galetto J et al.: The B-lymphocytic nature of the hairy cell of leukaemic reticuloendotheliosis. Brit J Haematol 1974 (26):29–37CrossRefGoogle Scholar
  15. 15.
    Golde DW, Stevens RH, Quan SG, Saxon A: Immunoglobulin synthesis in hairy cell leukaemia. Brit J Haematol 1977 (35):359–365CrossRefGoogle Scholar
  16. 16.
    Jansen J, Schuit HRE, Van Zwet TL et al.: Hairy cell leukaemia: a B-lymphocytic disorder. Brit J Haematol 1979 (42):21–33CrossRefGoogle Scholar
  17. 17.
    Jansen J, Den Ottolander GJ, Schuit HRE et al.: Hairy cell leukemia: Its place among the chronic B cell leukemias. Semin Oncol 1984 (11):386–393PubMedGoogle Scholar
  18. 18.
    Melo JV, San Miguel JF, Moss VE et al.: The membrane phenotype of hairy cell leukemia: A study with monoclonal antibodies. Semin Oncol 1984 (11):381–385PubMedGoogle Scholar
  19. 19.
    Korsmeyer SJ, Greene WC, Cossman J et al.: Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sei USA 1983 (80):4522–4526CrossRefGoogle Scholar
  20. 20.
    Yam LT, Li CY, Lam KW: Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med 1971 (284):357–360PubMedCrossRefGoogle Scholar
  21. 21.
    Schaefer HE, Hellriegel KP, Zach J et al.: Zytochemischer Polymorphismus der sauren Phosphatase bei Haarzell Leukaemie. Blut 1975 (31):365–370PubMedCrossRefGoogle Scholar
  22. 22.
    Golomb HM: Hairy cell leukemia: Lessons learned in twenty-five years. J Clin Oncol 1983 (1):652–656PubMedGoogle Scholar
  23. 23.
    Stewart DJ, Bodey GP: Infections in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer 1981 (47):801–805PubMedCrossRefGoogle Scholar
  24. 24.
    Jansen J, Hermans J: for the Collaborative Study Group: Splenectomy in hairy cell leukemia: A retrospective multicenter analysis. Cancer 1981 (47): 2066–2076PubMedCrossRefGoogle Scholar
  25. 25.
    Magee JM, McKenzie S, Filippa DA et al.: Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer 1985 (56):2557–2562PubMedCrossRefGoogle Scholar
  26. 26.
    Van Norman AS, Nagorney DM, Martin JK et al.: Splenectomy of hairy cell leukemia. A clinical review of 63 patients. Cancer 1986 (57):644–648PubMedCrossRefGoogle Scholar
  27. 27.
    Golde DW, Jacobs AD, Glaspy JA: Hairy cell leukemia: Biology and treatment. Semin Hematol 1986 (23, Suppl 1):472–478Google Scholar
  28. 28.
    Jansen J, den Ottolander GJ, Holdrinet RSG et al.: Prognosis and therapy in hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):472–478PubMedGoogle Scholar
  29. 29.
    McCarthy D, Catovsky D: Response to doxorubicin in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 1979 (54):298–304Google Scholar
  30. 30.
    Stewart DJ, Benjamin RS, McCredie KB: The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 1979 (54):298–304PubMedGoogle Scholar
  31. 31.
    Golomb HM, Schmidt K, Vardiman JW: Chlorambucil therapy of twenty-four post-splenectomy patients with progressive hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):502–506PubMedGoogle Scholar
  32. 32.
    Yam LT, Klock JC, Mielke CH: Therapeutic leukapheresis in hairy cell leukemia: Review of literature and personal experience. Semin Oncol 1984 (11, Suppl 2):493–501PubMedGoogle Scholar
  33. 33.
    Cheever MA, Fefer A, Greenberg PD et al.: Identical twin bone marrow transplantation for hairy cell leukemia. Semin Oncol 1984 (11, Suppl 2):511–513PubMedGoogle Scholar
  34. 34.
    Calvo F, Castaigne S, Sigaux F et al.: Intensive chemotherapy of hairy cell leukemia in patients with aggressive disease. Blood 1985 (65):115–119PubMedGoogle Scholar
  35. 35.
    Quesada JR, Reuben J, Manning JT et al.: Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984 (310):15–18PubMedCrossRefGoogle Scholar
  36. 36.
    Porzsolt F, Thomä J, Unsold W et al.: Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut 1985 (51)73–82PubMedCrossRefGoogle Scholar
  37. 37.
    Hofmann V, Fehr J, Sauter C et al.: Hairy cell leukemia: An interferon deficient disease? Cancer Treat Rev 1985 (12, Suppl B):33–37PubMedGoogle Scholar
  38. 38.
    Worman CP, Catovsky D, Bevan PC et al.: interferon is effective in hairy-cell leukaemia. Brit J Haematol 1985 (60):759–763CrossRefGoogle Scholar
  39. 39.
    Huber C, Flener R, Gastl G: lnterferon-alpha-2c in the treatment of advanced hairy cell leukaemia. Results of a phase II trial. Oncology 1985 (42, Suppl 1):7–9PubMedCrossRefGoogle Scholar
  40. 40.
    Quesada JR, Gutterman JU, Hersh EM: Treatment of hairy cell leukemia with alpha interferons. Cancer 1986 (57):1678–1680PubMedCrossRefGoogle Scholar
  41. 41.
    Quesada JR, Hersh EM, Manning J et al.: Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986 (68):493–497PubMedGoogle Scholar
  42. 42.
    Golomb HM, Jacobs A, Fefer A et al.: Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients. J Clin Oncol 1986 (4):900–905PubMedGoogle Scholar
  43. 43.
    Flandrin G, Sigaux F, Castaigne S et al.: Treatment of hairy cell leukemia with recombinant alpha interferon. I. Quantitative study of bone marrow changes during the first months of treatment. Blood 1986 (67):817–820PubMedGoogle Scholar
  44. 44.
    Niederle N, KLoke O, Nowrousian MR et al.: Efficacy of gamma and alpha interferon in the treatment of hairy cell leukemia. J Cancer Res Clin Oncol 1986 (111, Suppl):40CrossRefGoogle Scholar
  45. 45.
    Foon KA, Maluish AE, Abrams PG et al.: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Am J Med 1986 (80):351–356PubMedCrossRefGoogle Scholar
  46. 46.
    Ehmann WC, Silber R: Recombinant alpha-2 interferon for treatment of hairy cell leukemia without prior splenectomy. Am J Med 1986 (80):1111 -1114PubMedCrossRefGoogle Scholar
  47. 47.
    Smalley RV, Tuttle RL, Whisnant JK et al.: Effectiveness of Wellferon at a dose of 0.2 MU/m2 in the treatment of hairy cell leukemia. Blood 1986 (68, Suppl 1):233aGoogle Scholar
  48. 48.
    von Wussow P, Hill W, Diedrich H et al.: Low-dosage interferon alpha therapy of hairy cell leukemia. Blut 1986 (53):214Google Scholar
  49. 49.
    Huber C, Aulitzky W, Tilg H et al.: Studies on the optimal dose and the mode of action of interferon alpha in the treatment of hairy cell leukemia (HCL) Leukemia (in press)Google Scholar
  50. 50.
    Pralle H, Zwingers T, Boedewadt S et al.: A prospective multicenter trial with human recombinant interferon alpha-2c (Hr-lfn alpha 2c) in hairy cell leukemia (HCL) before and after splenectomy. Leukemia (in press)Google Scholar
  51. 51.
    Niederle N, Doberauer C, Kloke O et al.: Efficacy of gamma and alpha interferon on hairy cell leukemia. Klin Wochenschr (in press)Google Scholar
  52. 52.
    Castaigne S, Sigaux F, Canted K et al.: Interferon alpha in the treatment of hairy cell leukemia. Cancer 1986 (57):1681–1684PubMedCrossRefGoogle Scholar
  53. 53.
    Aulitzky W, Gastl G, Tilg H et al.: Recurrence of hairy cell leukemia upon discontinuation of IFN treatment. Blut 1986 (53):215Google Scholar
  54. 54.
    Ratain MJ, Golomb HM, Vardiman JW et al.: Duration of response of hairy cell leukemia after treatment with interferon alpha-2b. Blood 1986 (68, Suppl 1):229aGoogle Scholar
  55. 55.
    Gastl G, Aulitzky W, Leiter E et al.: Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing. Blut 1986 (52):273–279PubMedCrossRefGoogle Scholar
  56. 56.
    Paganelli KA, Evans SS, Han T et al.: B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 1986 (67):937–942PubMedGoogle Scholar
  57. 57.
    Porzsolt F, Janik R, Heil G et al.: Deficient IFN alpha production in hairy cell leukemia. Blut 1986 (52):185–190PubMedCrossRefGoogle Scholar
  58. 58.
    Stryckmans PA, Huygen K, Vanhaelen C et al.: In vitro production of alpha and gamma interferon by blood cells of patients with hairy cell leukemia. Blood 1986 (68, Suppl 1): 181aGoogle Scholar
  59. 59.
    Lepe-Zuniga JL, Quesada JR, Gutterman JU: Deficiency of production of alpha interferon in patients with active hairy cell leukemia and its restoration after complete remission. Blood 1986 (68, Suppl 1): 202aGoogle Scholar
  60. 60.
    Billard C, Sigaux F, Castaigne S et al.: Treatment of hairy cell leukemia with recombinant alpha interferon II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 1986 (67):821–826PubMedGoogle Scholar
  61. 61.
    Clark RH, Dimitrov NV, Axelson JA et al.: Intermittent alpha-leukocyte interferon in the treatment of hairy cell leukemia. Blood 1986 (68, Suppl 1):220aGoogle Scholar
  62. 62.
    Porzsolt F: Primary treatment of hairy cell leukemia: Should IFN-therapy replace splenectomy? Blut 1986 (52):265–272PubMedCrossRefGoogle Scholar
  63. 63.
    Ratain MJ, Vardiman JW, Golomb HM: Prognostic variables in hairy cell leukemia following splenectomy as initial therapy. Blood 1986 (68, Suppl 1):205aGoogle Scholar
  64. 64.
    Spiers ASD, Parekh SJ, Bishop MB: Hairy-cell leukemia: Induction of complete remission with pentostatin (2’- deoxycoformycin). J Clin Oncol 1984 (2):1336–1342PubMedGoogle Scholar
  65. 65.
    Foon KA, Nakano GM, Koller CA et al.: Response to 2’deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell leukemia. Blood 1986 (68):297–300PubMedGoogle Scholar
  66. 66.
    Ho AD, Dietz G, Trede I et al.: Enzymes of purine metabolism in hairy cell leukemia. Cancer 1986 (58):96–99PubMedCrossRefGoogle Scholar
  67. 67.
    Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951 (6):372–375PubMedGoogle Scholar
  68. 68.
    Fialkow PJ, Jakobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer J Med 1977 (63):125–130PubMedCrossRefGoogle Scholar
  69. 69.
    Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960 (132):1497Google Scholar
  70. 70.
    Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond) 1973 (243):290–293CrossRefGoogle Scholar
  71. 71.
    Sandberg A: Chromosomes and causation of human cancer and leukemia. XL. The Ph’ and other translocations in CML. Cancer 1980 (46):2221–2226PubMedCrossRefGoogle Scholar
  72. 72.
    Sokal JE, Gomez GA: The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia. J Clin Oncol 1986 (4):104–111PubMedGoogle Scholar
  73. 73.
    Heisterkamp N, Stephenson JR, Groffen J et al.: Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (Lond) 1983 (306):239–242CrossRefGoogle Scholar
  74. 74.
    Bartram CR, de Klein A, Hagemeijer A et al.: Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983 (306):277–280PubMedCrossRefGoogle Scholar
  75. 75.
    Shtivelman E, Lifshitz B, Gale RP et al.: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond) 1985 (315):550–554CrossRefGoogle Scholar
  76. 76.
    Stam K, Heisterkamp N, Grosveld G et al.: Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985 (313):1429–1433PubMedCrossRefGoogle Scholar
  77. 77.
    Kloetzer W, Kurzrock R, Smith L et al.: The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985 (140):230–238PubMedCrossRefGoogle Scholar
  78. 78.
    Canellos GP: Chronic granulocytic leukemia. Med Clin N Amer 1976 (60):1001–1018PubMedGoogle Scholar
  79. 79.
    Koeffler HP, Golde DW: Chronic myelogenous leukemia - New concepts (First of two parts). N Engl J Med 1981 (304):1201–1209PubMedCrossRefGoogle Scholar
  80. 80.
    Silver RT, Gale RP: Chronic myeloid leukemia. Amer J Med 1986 (80):1137–1147PubMedCrossRefGoogle Scholar
  81. 81.
    Minot GR, Buckman TE, Isaacs R: Chronic myelogenous leukemia; age incidence, duration and benefit derived from irradiation. JAMA 1924 (82):1489–1494CrossRefGoogle Scholar
  82. 82.
    Gollerkeri MP, Shah GB: Management of chronic myeloid leukemia. A five-year survey with a comparison of oral busulfan and splenic irradiation. Cancer 1971 (27):596–601PubMedCrossRefGoogle Scholar
  83. 83.
    Baker M, Taub RN, Carter WH Jr et al. and the Toronto Leukemia Study Group: Immunotherapy for chronic myelogenous leukemia: Survival not affected by treatment in the stable phase. Cancer Res 1984 (44):383–385PubMedGoogle Scholar
  84. 84.
    Arlin ZA, Mertelsmann R, Berman E et al.: 13-Cis-retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia. J Clin Oncol 1985 (4):473–476Google Scholar
  85. 85.
    Advani SH, Gulwani B, Ghogale SG et al.: Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia. Oncology 1985 (42):275–281PubMedCrossRefGoogle Scholar
  86. 86.
    Medical Research Council’s Working Party for Therapeutic Trials in Leukaemia: Chronic granulocytic leukaemia. Comparison of radiotherapy and busulphan therapy. Brit Med J 1968 (1):201–208Google Scholar
  87. 87.
    Ihde DC, Canellos GP, Schwartz JH et al.: Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. Ann Intern Med 1976 (84):17–21PubMedGoogle Scholar
  88. 88.
    Spiers ASD, Galton DAG, Kaur J et al.: Thioguanine as primary treatment for chronic granulocytic leukaemia. Lancet 1975 (l):829–832CrossRefGoogle Scholar
  89. 89.
    Singer CRJ, McDonald GA, Douglas AS: Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion. Brit J Haemat 1984 (57):309–313PubMedGoogle Scholar
  90. 90.
    Zago MA, Costa FF, Bottura C: Cytogenetic remission in a Ph-positive case of chronic myelogenous leukaemia. Scand J Haemat 1979 (22):91–95PubMedCrossRefGoogle Scholar
  91. 91.
    Hester JP, Waddell CC, Coltman CA Jr et al.: Response of chronic myelogenous leukemia patients to COAP- splenectomy. Cancer 1984 (54):1977–1982PubMedCrossRefGoogle Scholar
  92. 92.
    Kantarjian HM, Vellekoop L, McCredie KB et al.: Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 1985 (3):192–200PubMedGoogle Scholar
  93. 93.
    Fever A, Cheever MA, Greenberg BP et al.: Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 1982 (306):63–68CrossRefGoogle Scholar
  94. 94.
    Goldman JM, Apperley JF, Jones L et al.: Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986 (314):202PubMedCrossRefGoogle Scholar
  95. 95.
    Mahmoud HK, Schaefer UW, Schuening F et al.: Bone marrow transplantation for chronic granulocytic leukemia. Klin Wschr 1985 (63):560–564PubMedCrossRefGoogle Scholar
  96. 96.
    Thomas ED, Clift RA, Fefer A et al.: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986 (104):155–163PubMedGoogle Scholar
  97. 97.
    Greenberg PL, Mosny SA: Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 1977 (37):1794–1799PubMedGoogle Scholar
  98. 98.
    Verma DS, Spitzer G, Gutterman JU et al.: Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 1979 (54):1423–1427PubMedGoogle Scholar
  99. 99.
    Taetle R, Buick RN, McCulloch EA: Effect of interferon on colony formation in culture by blast cell progenitors in acute myeloblasts leukemia. Blood 1980 (56):549–552PubMedGoogle Scholar
  100. 100.
    Williams CKO, Svet-Moldavskaya I, Vilcek J et al.: Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981 (38):356–360PubMedCrossRefGoogle Scholar
  101. 101.
    Neumann HA, Fauser AA: Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 1982 (10):587–590PubMedGoogle Scholar
  102. 102.
    Broxmeyer HE, Lu L, Platzer E et al.: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983 (131):1300–1305PubMedGoogle Scholar
  103. 103.
    Tomida M, Yamamoto Y, Hozumi M: Stimulation by interferon of induction of differentiation of human promyelocyte leukemia cells. Biochem Biophys Res Commun 1982 (104):30–37PubMedCrossRefGoogle Scholar
  104. 104.
    Perussia B, Dayton ET, Fanning P et al.: Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway. J Exp Med 1983 (158):2058–2080PubMedCrossRefGoogle Scholar
  105. 105.
    Gutterman JU, Blumenschein GR, Alexanian R et al.: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980 (93):399–406PubMedGoogle Scholar
  106. 106.
    Niederle N, Kurschel E, Schmidt CG: Biologischer Effekt von rekombiniertem Leukozyten-alpha2-lnterferon bei metastasierten kolorektalen Karzinomen. Dtsch med Wschr 1984 (109):779–782PubMedCrossRefGoogle Scholar
  107. 107.
    Quesada JR, Swanson DA, Trindade A et al.: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 1983 (43):940–943PubMedGoogle Scholar
  108. 108.
    Talpaz M, McCredie KB, Keating MJ et al.: Clinical investigation of leukocyte interferon (HulFN-alpha) in chronic myelogenous leukemia. Blood 1983 (62):209aGoogle Scholar
  109. 109.
    Talpaz M, McCredie KB, Mavligit GM et al.: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983 (62):689–692PubMedGoogle Scholar
  110. 110.
    Talpaz M, McCredie K, Kantarjian H et al.: Chronic myelogenous leukaemia: Haematological remissions with alpha interferon. Brit J Haematol 1986 (64):87–95CrossRefGoogle Scholar
  111. 111.
    Rohatiner AZS, O’Brien M, Dhaliwal MS et al.: Experience with recombinant DNA interferon (IFN-alpha2) in patients with chronic leukaemia. 13th International Congress of Chemotherapy 1983:266/9–15, ViennaGoogle Scholar
  112. 112.
    Talpaz M, Kantarjian HM, McCredie KB et al.: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 1986 (314):1065–1069PubMedCrossRefGoogle Scholar
  113. 113.
    Diedrich H, von Wussow P, Freund M et al.: Treatment of chronic myelogenous leukemia with recombinant interferon alpha 2. Blut 1986 (53):236Google Scholar
  114. 114.
    Niederle N, Kloke O, May D et al.: Treatment of chronic myelogenous leukemia with recombinant interferon alpha 2b. Invest New Drugs (in press)Google Scholar
  115. 115.
    Gastl G, Aulitzky W, Tilg H et al.: Dose-related effectiveness of alpha interferon in chronic myelogenous leukemia. Blut (in press)Google Scholar
  116. 116.
    Morra E, Alimena G, Liberati AM et al.: Recombinant alpha 2 interferon (rIFN alpha2) in the treatment of chronic myelogenous leukemia. In: Program and Abstracts, 4th International Symposium on Therapy of Acute Leukemias, 299 (318), Roma 7–12 Feb. 1987Google Scholar
  117. 117.
    Kurzrock R, Talpaz M, Kantarjian H et al.: Phase II study of recombinant interferon-gamma in chronic myelogenous leukemia. Blood 1986 (68, Suppl 1):255aGoogle Scholar
  118. 118.
    Herrmann F, Lindemann A, Bambach T et al.: Recombinant interferon-gamma (rIFN-gamma) in benign phase CML: In vivo and in vitro results. In: Program and Abstracts, 4th International Symposium on Therapy of Acute Leukemias, 230 (184), Rome, 7–12 Feb, 1987Google Scholar
  119. 119.
    Talpaz M, Trujillo JM, Hittelman WN et al.: Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leukocyte interferon. Brit J Haematol 1985 (60):619–624CrossRefGoogle Scholar
  120. 120.
    Niederle N, Kloke O, Doberauer C et al.: Alpha-Interferon: Erste Behandlungsergebnisse bei der chronischen myeloischen Leukaemie. Dtsch med Wschr 1986 (111):767–772PubMedCrossRefGoogle Scholar
  121. 121.
    Geissler G, Gastl G, Konwalinka G et al.: Antileukemic effect of rIFN-alpha in CML: Comparison in vitro and in vivo. Blut 1986 (53):239–240Google Scholar
  122. 122.
    Talpaz M, Mavligit G, Keating M et al.: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Int Med 1983 (99):789–792PubMedGoogle Scholar
  123. 123.
    Niederle N, Kloke O, Osieka R et al.: Interferon alpha-2b in the treatment of chronic myelogenous leukemia. Semin Oncol (in press)Google Scholar
  124. 124.
    Wandl UB, Niederle N, Kloke O et al.: Chronic myelocytic leukaemia: Reduction of in vitro proliferation of haemopoietic progenitor cells in patients treated with recombinant alpha-interferon (IFN-alpha 2b). Blut 1986 (53):237Google Scholar
  125. 125.
    Kloke O, Becher R, Niederle N: Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia. Blut (submitted)Google Scholar
  126. 126.
    Maxwell BL, Talpaz M, Gutterman JU: Down regulation of peripheral blood cell interferon receptors in chronic myelogenous leukaemia patients undergoing human interferon (HulFN) therapy. Int J Cancer 1985 (36):23–28PubMedCrossRefGoogle Scholar
  127. 127.
    Bergsagel DE, Haas RH, Messner HA: Interferon alpha-2b in the treatment of chronic granulocytic leukemia. Sem Oncol 1986 (13, Suppl 2):29–34Google Scholar
  128. 128.
    Espinosa E, De Castro R, Carnot J et al.: Treatment of chronic myelocytic leukemia with human leukocyte alpha interferon. Abstr2nd Cuban Sem Interferon Biotechnol, Havana 1986Google Scholar
  129. 129.
    Kantarjian H, Talpaz M, Keating M et al.: Therapy of Philadelphia chromosome positive chronic myelogenous leukemia with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon (IFN-A). Blood 1986 (68, Suppl 1):224aGoogle Scholar
  130. 130.
    Silver RT, Reich SD, Coleman M et al.: Gamma interferon has activity in treating chronic myeloid leukemia. Blood 1986 (68, Suppl 1):232aGoogle Scholar
  131. 131.
    Fleischmann WR, Fleischmann CM, Fiers W: Potentiation of interferon action by mixtures of recombinant DNA- derived human interferons. Antiviral Res 1984 (4):357–360PubMedCrossRefGoogle Scholar
  132. 132.
    Denz H, Lechleitner M, Marth C et al.: Effect of human recombinant alpha 2 and gamma interferon on the growth of human cell lines from solid tumors and hematological malignancies. J Interferon Res 1985 (5):147–157PubMedCrossRefGoogle Scholar
  133. 133.
    McPherson TA, Tan YH: Phase I pharmatoxicology study of human fibroblast interferon in human cancers. J Natl Cancer Inst 1980 (65):75–79PubMedGoogle Scholar
  134. 134.
    Niederle N, Kurschel E, Schuette J et al.: Phase I study of human interferon gamma in patients with advanced cancer. In: Kirchner H and Schellekens K (eds) The biology of the interferon system 1984. Elsevier Science Publishers, Amsterdam 1985 pp 509–515Google Scholar
  135. 135.
    Foon KA, Sherwin SA, Abrams PG et al.: A Phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985 (20):193–197PubMedCrossRefGoogle Scholar
  136. 136.
    Vadhan-Raj S, Nathan CF, Sherwin SA et al.: Phase I trial of recombinant interferon gamma by 1-hour iv infusion. Cancer Treat Rep 1986 (70):609–614PubMedGoogle Scholar
  137. 137.
    Kurzrock R, Quesada JR, Talpaz M et al.: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 1986 (4):1101–1109PubMedGoogle Scholar
  138. 138.
    Quesada JR, Talpaz M, Rios A et al.: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986 (4):234–243PubMedGoogle Scholar
  139. 139.
    Averbuch SD, Austin HA, Sherwin SA et al.: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984 (310):32–35PubMedCrossRefGoogle Scholar
  140. 140.
    Selby P, Kohn J, Raymond J et al.: Nephrotic syndrome during treatment with interferon. Br Med J 1985 (290):1180CrossRefGoogle Scholar
  141. 141.
    Metz U, Kruschel E, Niederle N et al.: Urinary enzymes in the detection of the nephrotoxic potential of recombinant human alpha-interferon. In: Bach PH, Look EA (eds) Renal heterogeneity and target cell toxicity. John Wiley & Sons, Chichester-New York-Brisbane-Toronto-Singapore 1985 pp 267–270Google Scholar
  142. 142.
    Kurschel E, Metz-Kruschel U, Hofmann W et al.: Chronische myeloische Leukaemie - Untersuchungen zur Erfassung der Nephrotoxizitaet von humanem alpha-2b Interferon unter besonderer Beruecksichtigung der Analyse von Harnenzymen. Klin Wschr (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • Norbert Niederle
    • 1
  • Otto Kloke
    • 1
  1. 1.West-German Cancer CenterEssen 1Germany

Personalised recommendations